Hospital
Roper Hospital, INC
Roper Hospital, INC was paid $22.01M by Medicaid between Jan 2018 and Dec 2024, across 225 billing codes. Its largest line is 99283, emergency room visit (moderate) — 17% of everything it billed.
33Billing provider infoROPER HOSPITAL, INC
CHARLESTON, SC 29401
CHARLESTON, SC 29401
33aNPI1962472860assigned 01/24/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$22.01M
24GClaims641,573
24DCodes billed225
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in South Carolina
Rank by total paid#16 of 115
Median peer was paid$2.47M
This provider vs. median8.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 91,106 | $2.80M | |
| 2019 | 91,266 | $2.53M | |
| 2020 | 74,113 | $2.04M | |
| 2021 | 93,546 | $2.80M | |
| 2022 | 91,875 | $4.21M | |
| 2023 | 106,412 | $4.40M | |
| 2024incomplete | 93,255 | $3.25M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 63,220 | 57,427 | $3.64M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 8.3% | 14,231 | 13,291 | $1.82M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 6.8% | 10,116 | 9,070 | $1.49M |
| 81003 | 6.4% | 20,429 | 19,042 | $1.41M | |
| 80048 | Basic metabolic panel (calcium, ionized) | 6.1% | 24,540 | 20,922 | $1.35M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.1% | 14,788 | 13,418 | $895K |
| 80053 | Comprehensive metabolic panel | 3.6% | 17,600 | 15,655 | $792K |
| 36415 | Collection of venous blood by venipuncture | 3.4% | 12,984 | 10,956 | $749K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.5% | 11,242 | 9,671 | $545K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.2% | 32,555 | 29,612 | $479K |
| 81025 | 2.0% | 18,233 | 16,962 | $431K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.9% | 2,612 | 2,395 | $417K |
213 more codes
| 81001 | 1.6% | 10,094 | $350K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.5% | 18,521 | $336K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.4% | 2,299 | $309K |
| 87210 | 1.3% | 4,115 | $291K | |
| 87430 | 1.2% | 4,757 | $274K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.1% | 5,569 | $245K |
| 73630 | 1.1% | 2,488 | $241K | |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 8,487 | $237K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.0% | 1,774 | $230K |
| 73610 | <1% | 2,010 | $214K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 6,554 | $214K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 5,014 | $205K |
| 73130 | <1% | 1,551 | $192K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,545 | $181K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,702 | $180K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 6,931 | $173K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 361 | $168K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 6,676 | $145K |
| 87081 | <1% | 4,509 | $133K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,372 | $124K |
| 87077 | <1% | 6,365 | $111K | |
| 71045 | Radiologic examination, chest; single view | <1% | 10,734 | $111K |
| 73030 | <1% | 1,699 | $111K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 495 | $110K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 402 | $107K |
| 73562 | <1% | 1,477 | $106K | |
| 73110 | <1% | 957 | $99K | |
| 99285 | Emergency room visit (most serious) | <1% | 14,745 | $97K |
| 73140 | <1% | 538 | $93K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 132 | $91K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,867 | $90K |
| J3490 | Unclassified drugs | <1% | 491 | $88K |
| 84702 | <1% | 2,135 | $84K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,287 | $80K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 6,596 | $79K |
| 71250 | <1% | 429 | $76K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,170 | $75K |
| 87147 | <1% | 1,160 | $71K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,819 | $70K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,677 | $70K |
| 84132 | <1% | 1,982 | $67K | |
| A0425 | Ground mileage, per statute mile | <1% | 4,887 | $66K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,853 | $63K |
| A0427 | Emergency ambulance ride, advanced life support | <1% | 769 | $61K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,055 | $59K |
| 73560 | <1% | 956 | $57K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 60 | $57K |
| 72100 | <1% | 1,513 | $57K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 657 | $56K |
| 87070 | <1% | 4,082 | $56K | |
| 84484 | <1% | 10,891 | $56K | |
| 86900 | <1% | 3,394 | $53K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,002 | $51K |
| 86901 | <1% | 3,396 | $45K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 75 | $45K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,039 | $44K |
| 73502 | <1% | 1,196 | $44K | |
| 93971 | <1% | 257 | $38K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 27,632 | $37K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 414 | $35K |
| 86850 | <1% | 2,953 | $35K | |
| 87040 | <1% | 2,692 | $35K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 665 | $32K |
| 85027 | <1% | 14,445 | $32K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,703 | $30K |
| 85610 | <1% | 3,794 | $30K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 254 | $28K |
| 87428 | <1% | 151 | $27K | |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 2,985 | $25K |
| 97597 | <1% | 465 | $23K | |
| 80076 | <1% | 4,130 | $23K | |
| 96376 | <1% | 2,075 | $22K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 87 | $20K |
| 87075 | <1% | 606 | $19K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,241 | $18K |
| 74018 | <1% | 364 | $16K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 167 | $16K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 8,349 | $15K |
| 85379 | <1% | 3,133 | $14K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 983 | $14K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,714 | $13K |
| 72141 | <1% | 26 | $13K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 16,483 | $12K |
| C1769 | Guide wire | <1% | 1,084 | $12K |
| 97161 | <1% | 692 | $12K | |
| 95800 | <1% | 66 | $10K | |
| A0429 | Emergency ambulance ride, basic life support | <1% | 101 | $9K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 927 | $9K |
| 80061 | Lipid panel | <1% | 4,029 | $8K |
| 88304 | <1% | 173 | $8K | |
| G0378 | Hospital observation service, per hour | <1% | 3,316 | $7K |
| 84439 | <1% | 1,350 | $7K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 128 | $6K |
| 82550 | <1% | 2,146 | $6K | |
| 83605 | <1% | 4,191 | $6K | |
| 76830 | Ultrasound, transvaginal | <1% | 51 | $5K |
| 93458 | <1% | 26 | $5K | |
| 12001 | <1% | 163 | $5K | |
| A0426 | Ambulance service, advanced life support, non-emergency transport, level 1 (als 1) | <1% | 121 | $5K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 648 | $3K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 242 | $3K |
| 74019 | <1% | 151 | $3K | |
| 10061 | <1% | 367 | $3K | |
| 82570 | <1% | 471 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,767 | $3K |
| 87205 | <1% | 850 | $3K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,006 | $2K |
| 10060 | <1% | 123 | $2K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 30 | $2K |
| 72050 | <1% | 46 | $2K | |
| 87481 | <1% | 13 | $2K | |
| 73590 | <1% | 16 | $2K | |
| 0240U | <1% | 13 | $2K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 26 | $2K |
| 86140 | <1% | 266 | $2K | |
| 73090 | <1% | 25 | $2K | |
| 83880 | <1% | 4,154 | $1K | |
| 77080 | <1% | 12 | $1K | |
| 83690 | <1% | 9,006 | $1K | |
| 83735 | <1% | 6,293 | $1K | |
| 86592 | <1% | 179 | $1K | |
| 82728 | <1% | 527 | $1K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 766 | $917.44 |
| 97165 | <1% | 295 | $882.28 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 175 | $828.99 |
| J2704 | Injection, propofol, 10 mg | <1% | 2,215 | $798.72 |
| 72072 | <1% | 15 | $720.67 | |
| 83540 | <1% | 323 | $685.49 | |
| 73070 | <1% | 13 | $644.38 | |
| 70491 | <1% | 13 | $593.34 | |
| 82607 | <1% | 303 | $579.25 | |
| 87186 | <1% | 3,193 | $455.89 | |
| 82785 | <1% | 41 | $415.65 | |
| A9270 | Non-covered item or service | <1% | 7,584 | $391.69 |
| 72131 | <1% | 58 | $385.19 | |
| 80164 | <1% | 83 | $267.78 | |
| 70486 | <1% | 14 | $225.01 | |
| 83021 | <1% | 30 | $194.68 | |
| 90715 | <1% | 1,189 | $189.61 | |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 38 | $167.67 |
| 82950 | <1% | 92 | $160.64 | |
| 85660 | <1% | 33 | $127.88 | |
| 87807 | <1% | 16 | $125.41 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 842 | $115.92 |
| 87150 | <1% | 1,603 | $112.05 | |
| 84156 | <1% | 89 | $66.02 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 243 | $50.26 |
| 85730 | <1% | 930 | $46.85 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 291 | $37.25 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,186 | $29.95 |
| 85652 | <1% | 195 | $29.62 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,083 | $24.82 |
| 82043 | <1% | 42 | $4.21 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 313 | $4.17 |
| 85014 | 0% | 52 | $0.00 | |
| 76937 | 0% | 238 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 128 | $0.00 |
| 99152 | 0% | 131 | $0.00 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 539 | $0.00 |
| 82009 | 0% | 113 | $0.00 | |
| 84145 | 0% | 149 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 136 | $0.00 |
| 29125 | 0% | 77 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 68 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 192 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 662 | $0.00 |
| 86787 | 0% | 33 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 170 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 136 | $0.00 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 12 | $0.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 16 | $0.00 |
| C1776 | Joint device (implantable) | 0% | 15 | $0.00 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 0% | 27 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 12 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 12 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 25 | $0.00 |
| 64447 | 0% | 25 | $0.00 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 58 | $0.00 |
| 84100 | 0% | 64 | $0.00 | |
| 12011 | 0% | 25 | $0.00 | |
| 93976 | 0% | 14 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 50 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 1,659 | $0.00 |
| A0888 | Noncovered ambulance mileage, per mile (e.g., for miles traveled beyond closest appropriate facility) | 0% | 51 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 907 | $0.00 |
| 87340 | 0% | 85 | $0.00 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 2,141 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 1,378 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 136 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 1,175 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 59 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 279 | $0.00 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 199 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 238 | $0.00 |
| 97535 | Self-care/home management training, each 15 minutes | 0% | 15 | $0.00 |
| 87184 | 0% | 14 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 54 | $0.00 |
| 83550 | 0% | 186 | $0.00 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 497 | $0.00 |
| 36000 | 0% | 27 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 40 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 41 | $0.00 |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | 0% | 129 | $0.00 |
| 88342 | 0% | 25 | $0.00 | |
| 86747 | 0% | 34 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 98 | $0.00 |
| 86762 | 0% | 31 | $0.00 | |
| 84703 | 0% | 38 | $0.00 | |
| 85018 | 0% | 71 | $0.00 | |
| 84153 | 0% | 13 | $0.00 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 17 | $0.00 |
| 64450 | 0% | 13 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJOHNSON, BRET (CFO)
| Provider | Location | Paid |
|---|---|---|
| Bon Secours ST. Francis Xavier Hospital INC. | Charleston, SC | $35.85M |
| Bret M. Johnson DDS MS PS | Spokane, WA | $1.23M |
| Roper ST Francis Hospital-Berkeley INC. | Summerville, SC | $661K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.